Review ArticleReview

Immunology and immunotherapy in breast cancer

Vladimir Semiglazov, Andrey Tseluiko, Asel Kudaybergenova, Anna Artemyeva, Petr Krivorotko and Roman Donskih
Cancer Biology & Medicine May 2022, 19 (5) 609-618; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0597

References

  1. 1.↵
    2. Dunn GP,
    3. Bruce AT,
    4. Ikeda H,
    5. Old LJ,
    6. Schreiber RD.
    Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3: 991–8.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    2. Schreiber RD,
    3. Old LJ,
    4. Smyth MJ.
    Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331: 1565–70.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    2. Franzoi MA,
    3. Romano E,
    4. Piccart M.
    Immunotherapy for early breast cancer: too soon, too superficial, or just right? Ann Oncol. 2021; 32: 323–6.
    OpenUrl
  4. 4.
    2. Sobral-Leite M,
    3. van de Vijver K,
    4. Michaut M,
    5. van der Linden R,
    6. Hooijer GKJ,
    7. Horlings HM et al.
    Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. Oncoimmunology. 2018; 7: e1509820.
  5. 5.↵
    2. Stanton SE,
    3. Adams S,
    4. Disis ML.
    Variation in the incidence and magnitude of tumor infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016; 2: 1354–60.
    OpenUrl
  6. 6.↵
    2. Tseluiko A,
    3. Semiglazov V,
    4. Kudaibergenova A,
    5. Urezkova M,
    6. Artemieva A,
    7. Krivorotko P.
    The role of tumor-infiltrating lymphocytes, prognostic and predictive signification in breast cancer. 17th St. Gallen International Breast Cancer Conference/The Breast 56S1; 2021: P118, S65.
  7. 7.↵
    2. Esteva FJ,
    3. Hubbard-Lucey VM,
    4. Tang J,
    5. Pusztai L.
    Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019; 20: e175–86.
    OpenUrlPubMed
  8. 8.↵
    2. Cimino-Mathews A,
    3. Thompson E,
    4. Taube JM,
    5. Ye X,
    6. Lu Y,
    7. Meeker A, et al.
    PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016; 47: 52–63.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Butterfield L,
    3. Kaufman H,
    4. Marincola F,
    5. Sectrion IV,
    6. Ascieto P, editors.
    2. Emens L,
    3. Nanda R.
    Breast cancer immunotherapy. Butterfield L, Kaufman H, Marincola F, Sectrion IV, Ascieto P, editors. Cancer immunotherapy. Principal and practice. 2017, 702–16 [chapter 46].
  10. 10.↵
    2. Savas P,
    3. Salgado R,
    4. Denkert C,
    5. Sotiriou C,
    6. Darcy PK,
    7. Smyth MJ, et al.
    Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016; 13: 228–41.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Loi S,
    3. Michiels S,
    4. Loibl S,
    5. Budczies J,
    6. Denkert C,
    7. Adams S, et al.
    The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. Ann Oncol. 2021; 32: 1236–44.
    OpenUrl
  12. 12.
    2. Park JH,
    3. Jonas SF,
    4. Bataillon G,
    5. Criscitiello C,
    6. Salgado R,
    7. Loi S, et al.
    Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. Ann Oncol. 2019; 30: 1941–49.
    OpenUrlPubMed
  13. 13.
    2. De Jong VMT,
    3. Wang Y,
    4. Opdam M,
    5. ter Hoeve N,
    6. Jóźwiak K,
    7. Hauptmann M, et al.
    Prognostic value of tumour-infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group. Ann Oncol. 2020; 31: S303–39.
    OpenUrl
  14. 14.
    2. Salgado R,
    3. Denkert C,
    4. Campbell C,
    5. Savas P,
    6. Nuciforo P,
    7. Aura C, et al.
    Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 2015; 1: 448–54.
    OpenUrl
  15. 15.↵
    2. Ali HR,
    3. Provenzano E,
    4. Dawson S-J,
    5. Blows FM,
    6. Liu B,
    7. Shah M, et al.
    Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014; 25: 1536–43.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    2. Dieci MV,
    3. Mathieu MC,
    4. Guarneri V,
    5. Conte P,
    6. Delaloge S,
    7. Andre F, et al.
    Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015; 26: 1698–704.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Loi S,
    3. Michiels S,
    4. Salgado R,
    5. Sirtaine N,
    6. Jose V,
    7. Fumagalli D, et al.
    Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25: 1544–50.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    2. Perez EA,
    3. Ballman KV,
    4. Tenner KS,
    5. Thompson EA,
    6. Badve SS,
    7. Bailey H, et al.
    Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol. 2016; 2: 56–64.
    OpenUrl
  19. 19.↵
    2. Denkert C,
    3. Von Minckwitz G,
    4. Brase JC,
    5. Sinn BV,
    6. Gade G,
    7. Kronenwett R, et al.
    Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015; 33: 983–91.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    2. Cortazar P,
    3. Zhang L,
    4. Untch M,
    5. Mehta K,
    6. Costantino JP,
    7. Wolmark N, et al.
    Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014; 384: 164–72.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    2. Urezkova M,
    3. Kudaybergenova A,
    4. Semiglazova T,
    5. Semiglazov V,
    6. Tseluiko A,
    7. Artemyeva A, et al.
    TILs in triple – positive breast cancer. 17th St Gallen breast cancer conference, 2021, Poster Abstract/The Breast 56S1(2021), P027, S17–90.
  22. 22.↵
    2. Disis ML,
    3. Stanton SE.
    Triple negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book. 2015; 35: e25–30.
    OpenUrl
  23. 23.↵
    2. Stephens PJ,
    3. Tarpey PS,
    4. Davies H,
    5. Loo PV,
    6. Greenman C,
    7. Wedge DC, et al.
    Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486: 400–4.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    2. Smid M,
    3. Hoes M,
    4. Sieuwerts AM,
    5. Sleijfer S,
    6. Zhang Y,
    7. Wang Y, et al.
    Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes. Breast Cancer Res Treat. 2011; 128: 23–30.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490: 61–70.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.
    2. Banerji S,
    3. Cibulskis K,
    4. Rangel-Escareno C,
    5. Brown KK,
    6. Carter SL,
    7. Frederick AM, et al.
    Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012; 486: 405–9.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    2. Creighton CJ.
    The molecular profile of luminal B breast cancer. Biologics. 2012; 6: 289–97.
    OpenUrlPubMed
  28. 28.↵
    2. Abramson VG,
    3. Lehmann BD,
    4. Ballinger TJ,
    5. Pietenpol JA.
    Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015; 121: 8–16.
    OpenUrlCrossRefPubMed
  29. 29.↵
    2. Petersen J,
    3. Wurzbacher SJ,
    4. Williamson NA,
    5. Ramarathinam SH,
    6. Reid HH,
    7. Nair AK, et al.
    Phosphorylated self-peptides alter human leukocyte antigen class I-restricted antigen presentation and generate tumor-specific epitopes. Proc Natl Acad Sci U S A. 2009; 106: 2776–81.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    2. Rody A,
    3. Karn T,
    4. Liedtke C,
    5. Pusztai L,
    6. Ruckhaeberle E,
    7. Hanker L, et al.
    A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011; 13: R97.
    OpenUrlCrossRefPubMed
  31. 31.↵
    2. Denkert C,
    3. Loibl S,
    4. Noske A,
    5. Roller M,
    6. Müller BM,
    7. Komor M, et al.
    Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010; 28: 105–13.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    2. Liu S,
    3. Lachapelle J,
    4. Leung S,
    5. Gao D,
    6. Foulkes WD,
    7. Nielsen TO.
    CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012; 14: R48.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Müller P,
    3. Kreuzaler M,
    4. Khan T,
    5. Thommen DS,
    6. Martin K,
    7. Glatz K, et al.
    Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci Transl Med. 2015; 7: 315ra188.
  34. 34.↵
    2. Bates GJ,
    3. Fox SB,
    4. Han C,
    5. Leek RD,
    6. Garcia JF,
    7. Harris AL, et al.
    Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006; 24: 5373–80.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    2. Liu S,
    3. Foulkes WD,
    4. Leung S,
    5. Gao D,
    6. Lau S,
    7. Kos Z, et al.
    Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res. 2014; 16: 432.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    2. Lu L,
    3. Cantor H.
    Generation and regulation of CD8(+) regulatory T cells. Cell Mol Immunol. 2008; 5: 401–6.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Liu F,
    3. Lang R,
    4. Zhao J,
    5. Zhang X,
    6. Pringle GA,
    7. Fan Y, et al.
    CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011; 130: 645–55.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    2. Tolaney SM,
    3. Barroso-Sousa R,
    4. Keenan T,
    5. Li T,
    6. Trippa L,
    7. Vaz-Luis I, et al.
    Effect of eribulin with or without pembrolizumab on progression-free survival for patients with hormone receptor–positive, ERBB2-Negative Metastatic Breast Cancer: a randomized clinical trial [Internet]. JAMA Oncol. 2020; 6: 1355–62.
    OpenUrl
  39. 39.↵
    2. Yee D,
    3. DeMichele AM,
    4. Yau C,
    5. Isaacs C,
    6. Symmans WF,
    7. Albain KS, et al.
    I-SPY2 Trial Consortium: Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, et al. Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 adaptively randomized clinical trial. JAMA Oncol. 2020, 6: 1355–62.
    OpenUrl
  40. 40.
    2. Nanda R,
    3. Liu MC,
    4. Yau C,
    5. Shatsky R,
    6. Pusztai L,
    7. Wallace A, et al.
    Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020; 6: 676–84.
    OpenUrl
  41. 41.↵
    2. Liu MC,
    3. Robinson PA,
    4. Yau C,
    5. Wallace AM,
    6. Chien A,
    7. Stringer-Reasor E, et al.
    Evaluation of a pembrolizumab-8 cycle neoadjuvant regimen without AC for high-risk early-stage HER2-negative breast cancer: results from the I-SPY 2 TRIAL. Presented at the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. Abstract P3-09-02.
  42. 42.↵
    2. Terranova-Barberio M,
    3. Pawlowska N,
    4. Dhawan M,
    5. Moasser M,
    6. Chien AJ,
    7. Melisko ME, et al.
    Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer. Nat Commun. 2020; 11: 3584.
    OpenUrl
  43. 43.↵
    2. Liu F,
    3. Li Y,
    4. Ren M,
    5. Zhang X,
    6. Guo X,
    7. Lang R, et al.
    Peritumoral FOXP3+ regulatory T cell is sensitive to chemotherapy while intratumoral FOXP3+ regulatory T cell is prognostic predictor of breast cancer patients. Breast Cancer Res Treatment. 2012; 135: 459–67.
    OpenUrlPubMed
  44. 44.↵
    2. Miyashita M,
    3. Sasano H,
    4. Tamaki K,
    5. Hirakawa H,
    6. Takahashi Y,
    7. Nakagawa S, et al.
    Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015; 17: 124.
    OpenUrlPubMed
  45. 45.↵
    2. Mahmoud SMA,
    3. Paish EC,
    4. Powe DG,
    5. Macmillan RD,
    6. Grainge MJ,
    7. Lee AHS, et al.
    Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011; 29: 1949–55.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    2. Mahmoud SMA,
    3. Paish EC,
    4. Powe DG,
    5. Macmillan RD,
    6. Lee AH,
    7. Ellis IO, et al.
    An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat. 2011; 127: 99–108.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    2. Oda N,
    3. Shimazu K,
    4. Naoi Y,
    5. Morimoto K,
    6. Shimomura A,
    7. Shimoda M, et al.
    Intratumoral regulatory T cells as an independent predictive factor for pathological complete response to neoadjuvant paclitaxel followed by 5-FU/epirubicin/cyclophosphamide in breast cancer patients. Breast Cancer Res Treat. 2012; 136: 107–16.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    2. West NR,
    3. Kost SE,
    4. Martin SD,
    5. Milne K,
    6. Deleeuw RJ,
    7. Nelson BH, et al.
    Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor negative breast cancer. Br J Cancer. 2013; 108: 155–62.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    2. Andre F,
    3. Dieci MV,
    4. Dubsky P,
    5. Sotiriou C,
    6. Curigliano G,
    7. Denkert C, et al.
    Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2013; 19: 28–33.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    2. Luen S,
    3. Virassamy B,
    4. Savas P,
    5. Salgado R,
    6. Loi S.
    The genomic landscape of breast cancer and its interaction with host immunity. Breast. 2016; 29: 241–50.
    OpenUrlCrossRefPubMed
  51. 51.
    2. Denkert C,
    3. von Minckwitz G,
    4. Darb-Esfahani S,
    5. Lederer B,
    6. Heppner BI,
    7. Weber KE, et al.
    Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018; 19: 40–50.
    OpenUrlPubMed
  52. 52.
    2. Loi S,
    3. Drubay D,
    4. Adams S,
    5. Pruneri G,
    6. Francis PA,
    7. Lacroix-Triki M, et al.
    Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019; 37: 559–69.
    OpenUrlCrossRefPubMed
  53. 53.↵
    2. Mittendorf EA,
    3. Philips AV,
    4. Meric-Bernstam F,
    5. Qiao N,
    6. Wu Y,
    7. Harrington S, et al.
    PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014; 2: 361.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    2. Sabatier R,
    3. Finetti P,
    4. Mamessier E,
    5. Adelaide J,
    6. Chaffanet M,
    7. Ali HR, et al.
    Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015; 6: 5449–64.
    OpenUrlCrossRefPubMed
  55. 55.↵
    2. Galluzzi L,
    3. Buqué A,
    4. Kepp O,
    5. Zitvogel L,
    6. Kroemer G.
    Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015; 28: 690–714.
    OpenUrlCrossRefPubMed
  56. 56.↵
    2. Schmid P,
    3. Adams S,
    4. Rugo HS,
    5. Schneeweiss A,
    6. Barrios CH,
    7. Iwata H, et al.
    Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018; 379: 2108–21.
    OpenUrlCrossRefPubMed
  57. 57.↵
    2. Schmid P,
    3. Rugo HS,
    4. Adams S,
    5. Schneeweiss A,
    6. Barrios CH,
    7. Iwata H, et al.
    Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44–59.
    OpenUrlCrossRefPubMed
  58. 58.↵
    2. Voorwerk L,
    3. Slagter M,
    4. Horlings HM,
    5. Sikorska K,
    6. van de Vijver KK,
    7. de Maaker M, et al.
    Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019; 25: 920–8.
    OpenUrlPubMed
  59. 59.↵
    2. Emens LA,
    3. Adams S,
    4. Barrios CH,
    5. Diéras V,
    6. Iwata H,
    7. Loi S, et al.
    First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021; 32: 983–93.
    OpenUrl
  60. 60.↵
    2. Miles D,
    3. Gligorov J,
    4. André F,
    5. Cameron D,
    6. Schneeweiss A,
    7. Barrios C, et al.
    Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021; 32: 994–1004.
    OpenUrlCrossRef
  61. 61.↵
    2. Cortes J,
    3. Cescon DW,
    4. Rugo HS,
    5. Nowecki Z,
    6. Im SA,
    7. Yusof MM, et al.
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020; 396: 1817–28.
    OpenUrlCrossRefPubMed
  62. 62.↵
    2. Voorwerk L,
    3. Kok M.
    ‘IMpassionate conflicts’ in immunotherapy trials for metastatic triple-negative breast cancer. Ann Oncol. 2021; 32: 947–9.
    OpenUrl
  63. 63.↵
    2. Schmid P,
    3. Cortes J,
    4. Pusztai L,
    5. McArthur H,
    6. Kümmel S,
    7. Bergh J, et al.
    Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020; 382: 810–21.
    OpenUrlCrossRefPubMed
  64. 64.↵
    2. Cain DW,
    3. Cidlowski JA.
    Immune regulation by glucocorticoids. Nat Rev Immunol. 2017; 17: 233–47.
    OpenUrlCrossRefPubMed
  65. 65.↵
    2. Petrelli F,
    3. Signorelli D,
    4. Ghidini M,
    5. Ghidini A,
    6. Pizzutilo EG,
    7. Ruggieri L, et al.
    Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2020; 12: 546.
    OpenUrl
  66. 66.↵
    2. Zitvogel L,
    3. Apetoh L,
    4. Ghiringhelli F,
    5. Kroemer G.
    Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008; 8: 59–73.
    OpenUrlCrossRefPubMedWeb of Science
  67. 67.↵
    2. Keenan TE,
    3. Tolaney SM.
    Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020; 18: 479–89.
    OpenUrlPubMed
  68. 68.↵
    2. Mittendorf EA,
    3. Zhang H,
    4. Barrios CH,
    5. Saji S,
    6. Jung KH,
    7. Hegg R, et al.
    Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020; 396: 1090–100.
    OpenUrlCrossRefPubMed
  69. 69.↵
    2. Gianni L,
    3. Huang CS,
    4. Egle D,
    5. Bermejo B,
    6. Zamagni C,
    7. Thill M, et al.
    Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Presented at the 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019, San Antonio, Texas. Abstract GS3-04. 37.
  70. 70.↵
    2. Gianni L,
    3. Huang C-S,
    4. Egle D,
    5. Bermejo B,
    6. Zamagni C,
    7. Thill M, et al.
    Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study. Cancer Res. 2020; 80: GS3–04.
    OpenUrl
  71. 71.↵
    2. Loibl S,
    3. Untch M,
    4. Burchardi N,
    5. Huober J,
    6. Sinn BV,
    7. Blohmer JU, et al.
    A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol. 2019; 30: 1279–88.
    OpenUrlCrossRefPubMed
  72. 72.↵
    2. Loibl S,
    3. Schneeweiss A,
    4. Huober JB,
    5. Braun M,
    6. Rey J,
    7. Blohmer JU, et al.
    Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). J Clin Oncol. 2021; 39: 506.
    OpenUrl
  73. 73.↵
    2. Bianchini G,
    3. Huang C,
    4. Egle D,
    5. Bermejo B,
    6. Zamagni C,
    7. Yhill M, et al.
    LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial. Ann Oncol. 2020; 31: S1142–215.
    OpenUrl
  74. 74.↵
    2. Semiglazov VF,
    3. Tseluiko AI,
    4. Baldueva IA,
    5. Nekhaeva TL,
    6. Artemyeva AS,
    7. Kudaybergenova AG, et al.
    Immunology and immunotherapy in the complex treatment of malignant tumors. Meditsinskiy sovet = Medical Council. 2021; 248–257 (in Russian).
  75. 75.↵
    2. Zhang Y,
    3. Wang S,
    4. Yang B,
    5. Lu S,
    6. Du Y,
    7. Liu H.
    Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients. Cancer Biol Med. 2019; 16: 350–60.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    2. Loriot Y,
    3. Marabelle A,
    4. Guégan JP,
    5. Danlos FX,
    6. Besse B,
    7. Chaput N, et al.
    Plasma proteomics identifies Leukemia Inhibitory Factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. 2021; 32: S1381–90.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords